BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amlashi FG, Tritos NA. Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management. Endocrine 2016;52:427-40. [DOI: 10.1007/s12020-016-0863-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Tritos NA. Recent advances in medical therapies for pituitary adenomas. International Journal of Endocrine Oncology 2017;4:151-4. [DOI: 10.2217/ije-2017-0017] [Reference Citation Analysis]
2 Safi S, Benabdelfedil Y, Derrou S, El Guendouz F. Simultaneous Coexistence of Thyrotropin-Prolactin-Secreting Adenoma and Papillary Thyroid Carcinoma. Case Rep Endocrinol 2021;2021:6564765. [PMID: 34888106 DOI: 10.1155/2021/6564765] [Reference Citation Analysis]
3 Shah SS, Aghi MK. The Role of Single-Nucleotide Polymorphisms in Pituitary Adenomas Tumorigenesis. Cancers (Basel) 2019;11:E1977. [PMID: 31818039 DOI: 10.3390/cancers11121977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Mazziotti G, Frara S, Giustina A. Pituitary Diseases and Bone. Endocr Rev 2018;39:440-88. [PMID: 29684108 DOI: 10.1210/er.2018-00005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 17.7] [Reference Citation Analysis]
5 Olmedilla Y, Khan S, Young V, Joseph R, Cudlip S, Ansgorge O, Grossman A, Pal A. Plurihormonal Pit-1 lineage adenoma presenting as meningitis with recurrence after somatostatin analogue. Endocrinol Diabetes Metab Case Rep 2019;2019:EDM180130. [PMID: 30897548 DOI: 10.1530/EDM-18-0130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Sakata K, Fujimori K, Komaki S, Furuta T, Sugita Y, Ashida K, Nomura M, Morioka M. Pituitary Gangliocytoma Producing TSH and TRH: A Review of "Gangliocytomas of the Sellar Region". J Clin Endocrinol Metab 2020;105:dgaa474. [PMID: 32706866 DOI: 10.1210/clinem/dgaa474] [Reference Citation Analysis]
7 Saeger W, Koch A. Clinical Implications of the New WHO Classification 2017 for Pituitary Tumors. Exp Clin Endocrinol Diabetes 2021;129:146-56. [PMID: 33690870 DOI: 10.1055/a-1310-7900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Perdomo CM, Árabe JA, Idoate MÁ, Galofré JC. Management of a pregnant woman with thyrotropinoma: a case report and review of the literature. Gynecol Endocrinol 2017;33:188-92. [PMID: 27910710 DOI: 10.1080/09513590.2016.1260110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Deng F, Yang ZY, Zhang YP, Wang YL, Hu JY, Zhang F. TSH adenoma and syndrome of resistance to thyroid hormones-Two cases report of syndrome of inappropriate secretion of thyrotropin. Brain Behav 2021;11:e02081. [PMID: 33751836 DOI: 10.1002/brb3.2081] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Yoshiki K, Sasagawa Y, Shimojima M, Takeshita Y, Takata S, Hayashi Y, Takamura T, Tachibana O, Nakada M. Thyrotropin-secreting pituitary adenomas induce left atrial enlargement with subclinical atrial fibrillation: an echocardiographic study. Pituitary 2021;24:778-86. [PMID: 34009499 DOI: 10.1007/s11102-021-01154-3] [Reference Citation Analysis]
11 Timmons JG, Mukhopadhyay B. Hyperthyroxinemia with a non-suppressed TSH: how to confidently reach a diagnosis in this clinical conundrum. Hormones (Athens) 2020;19:311-5. [PMID: 32128699 DOI: 10.1007/s42000-020-00180-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Solari D, Pivonello R, Caggiano C, Guadagno E, Chiaramonte C, Miccoli G, Cavallo LM, Del Basso De Caro M, Colao A, Cappabianca P. Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us? World Neurosurg 2019;127:695-709. [PMID: 31266132 DOI: 10.1016/j.wneu.2019.03.049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
13 Chin SO. Epidemiology of Functioning Pituitary Adenomas. Endocrinol Metab (Seoul) 2020;35:237-42. [PMID: 32615708 DOI: 10.3803/EnM.2020.35.2.237] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Marques JVO, Boguszewski CL. Fertility issues in aggressive pituitary tumors. Rev Endocr Metab Disord 2020;21:225-33. [DOI: 10.1007/s11154-019-09530-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yang C, Wu H, Wang J, Hu M, Xing X, Bao X, Wang R. Successful management of octreotide-insensitive thyrotropin-secreting pituitary adenoma with bromocriptine and surgery: A case report and literature review. Medicine (Baltimore) 2017;96:e8017. [PMID: 28885368 DOI: 10.1097/MD.0000000000008017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
16 Trummer C, Reiher H, Theiler-Schwetz V, Pandis M, Gstettner C, Potzinger P, Keck T, Pieber TR, Lax S, Haybaeck J, Stepan V, Pilz S. Secondary Hyperthyroidism due to an Ectopic Thyrotropin-Secreting Neuroendocrine Pituitary Tumor: A Case Report. Eur Thyroid J 2020;9:106-12. [PMID: 32257960 DOI: 10.1159/000505020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Aydin B, Yildirim E, Erdogan O, Arga KY, Yilmaz BK, Bozkurt SU, Bayrakli F, Turanli B. Past, Present, and Future of Therapies for Pituitary Neuroendocrine Tumors: Need for Omics and Drug Repositioning Guidance. OMICS 2022;26:115-29. [PMID: 35172108 DOI: 10.1089/omi.2021.0221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Luo P, Zhang L, Yang L, An Z, Tan H. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor. Front Endocrinol (Lausanne) 2020;11:580264. [PMID: 33329389 DOI: 10.3389/fendo.2020.580264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Fu H, Cheng L, Jin Y, Chen L. Thyrotoxicosis with concomitant thyroid cancer. Endocr Relat Cancer 2019;26:R395-413. [PMID: 31026810 DOI: 10.1530/ERC-19-0129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Iglesias P, Rodríguez Berrocal V, Díez JJ. Giant pituitary adenoma: histological types, clinical features and therapeutic approaches. Endocrine 2018;61:407-21. [DOI: 10.1007/s12020-018-1645-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
21 Wildemberg LE, Kasuki L, Gadelha MR. Precision medicine in the medical management of pituitary tumors. Current Opinion in Endocrine and Metabolic Research 2018;1:57-62. [DOI: 10.1016/j.coemr.2018.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Banskota S, Adamson DC. Pituitary Adenomas: From Diagnosis to Therapeutics. Biomedicines 2021;9:494. [PMID: 33946142 DOI: 10.3390/biomedicines9050494] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Saeger W. [The 2017 WHO classification of pituitary tumors]. Pathologe 2021;42:333-51. [PMID: 33877399 DOI: 10.1007/s00292-021-00932-x] [Reference Citation Analysis]
24 Li X, Lynch L, Xing H, Wang Z, Zhu J, Deng K, Wang R, Yao Y, Lian X. Cosecreting TSH/GH pituitary adenomas-an 8-year experience in a single tertiary center. Pituitary 2020;23:573-81. [PMID: 32681450 DOI: 10.1007/s11102-020-01064-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Stathatos N. Anatomy and Physiology of the Thyroid Gland. In: Luster M, Duntas LH, Wartofsky L, editors. The Thyroid and Its Diseases. Cham: Springer International Publishing; 2019. pp. 3-12. [DOI: 10.1007/978-3-319-72102-6_1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Cossu G, Daniel RT, Pierzchala K, Berhouma M, Pitteloud N, Lamine F, Colao A, Messerer M. Thyrotropin-secreting pituitary adenomas: a systematic review and meta-analysis of postoperative outcomes and management. Pituitary 2019;22:79-88. [PMID: 30390277 DOI: 10.1007/s11102-018-0921-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
27 Sharma A, Stan MN. Thyrotoxicosis: Diagnosis and Management. Mayo Clin Proc 2019;94:1048-64. [PMID: 30922695 DOI: 10.1016/j.mayocp.2018.10.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
28 Yang Y, Liu J, Deng K, Lu L, Zhu H, Lian X, Bao X, Duan L, Yao Y. Clinical and Therapeutic Characteristics of Pituitary TSH-Secreting Adenoma in Adolescent-Onset Patients: Six Case Studies and Literature Review. Front Endocrinol (Lausanne) 2021;12:771673. [PMID: 35002961 DOI: 10.3389/fendo.2021.771673] [Reference Citation Analysis]
29 Frara S, Losa M, Doga M, Formenti AM, Mortini P, Mazziotti G, Giustina A. High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma. J Endocr Soc 2018;2:1089-99. [PMID: 30202830 DOI: 10.1210/js.2018-00091] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
30 Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM; European Society of Endocrinology. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178:G1-G24. [PMID: 29046323 DOI: 10.1530/eje-17-0796] [Cited by in Crossref: 177] [Cited by in F6Publishing: 100] [Article Influence: 35.4] [Reference Citation Analysis]
31 Faltermeier CM, Magill ST, Blevins LS Jr, Aghi MK. Molecular Biology of Pituitary Adenomas. Neurosurg Clin N Am 2019;30:391-400. [PMID: 31471046 DOI: 10.1016/j.nec.2019.05.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
32 Thomasian NM, Kamel IR, Bai HX. Machine intelligence in non-invasive endocrine cancer diagnostics. Nat Rev Endocrinol 2021. [PMID: 34754064 DOI: 10.1038/s41574-021-00543-9] [Reference Citation Analysis]
33 Tirosh A, Shimon I. Complications of acromegaly: thyroid and colon. Pituitary 2017;20:70-5. [DOI: 10.1007/s11102-016-0744-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
34 Huang W, Molitch ME. Pituitary Tumors in Pregnancy. Endocrinol Metab Clin North Am 2019;48:569-81. [PMID: 31345524 DOI: 10.1016/j.ecl.2019.05.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
35 Iglesias P, Magallón R, Mitjavila M, Rodríguez Berrocal V, Pian H, Díez JJ. Multimodal therapy in aggressive pituitary tumors. Endocrinol Diabetes Nutr (Engl Ed) 2020;67:469-85. [PMID: 31740190 DOI: 10.1016/j.endinu.2019.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kim D, Ku CR, Park SH, Moon JH, Kim EH, Kim SH, Lee EJ. Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas. World Neurosurg 2018;115:e464-71. [PMID: 29678704 DOI: 10.1016/j.wneu.2018.04.070] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
37 Li X, Zhao B, Hou B, Wang J, Zhu J, Yao Y, Lian X. Case Report and Literature Review: Ectopic Thyrotropin-Secreting Pituitary Adenoma in the Suprasellar Region. Front Endocrinol (Lausanne) 2021;12:619161. [PMID: 33776916 DOI: 10.3389/fendo.2021.619161] [Reference Citation Analysis]